SynthesisEuropean journal of nuclear medicine and molecular imaging2026
Diagnostic accuracy of PSMA-targeted radioguided surgery in prostate cancer at multiple anatomical levels: a systematic review and meta-analysis.
Synthesis in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate-specific membrane antigen (PSMA)-targeted radioguided surgery (PSMA-RGS) is a promising intraoperative technique for improving lesion localization and surgical accuracy in prostate cancer (PCa), particularly in high-risk or recurrent cases.
objectiveTo systematically evaluate the diagnostic performance of PSMA-RGS in PCa using multilevel meta-analysis.
methodsFollowing PRISMA 2020 guidelines, we searched PubMed, Embase, and Web of Science for clinical studies published between January 2016 and May 2025, with the final search performed on May 1, 2025, and identified 28 eligible studies. Diagnostic accuracy was assessed at the patient, lesion, region, and lymph node levels, using pooled sensitivity, specificity, likelihood ratios, and diagnostic odds ratios (DOR). Random-effects meta-analyses were conducted and risk of bias was evaluated with the ROBINS-I tool.
resultsEx vivo PSMA-RGS demonstrated the highest specificity (up to 100%), while in vivo PSMA-RGS showed excellent sensitivity (90–97%) and specificity (90–99%), particularly at the lymph node level. Across all evaluated anatomical levels, PSMA-RGS consistently outperformed preoperative imaging (log DOR: 5.77 vs. 2.99; p < 0.0001). All diagnostic results were confirmed by histopathology as the reference standard. Meta-regression identified in vivo PSMA-RGS, lymph node–based analysis, and γ-probes combined with high-purity germanium detectors—used for post-resection confirmation—as independent predictors of improved diagnostic performance.
conclusionPSMA-RGS demonstrates robust diagnostic accuracy across multiple analytical levels, including per-patient, per-lesion, and per-node assessments. Initial evidence suggests that intraoperative γ-probes guidance may enable real-time localization of otherwise undetected nodal metastases. In high-risk prostate cancer surgery, this approach may help refine intraoperative decision-making, improve resection completeness, and reduce recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.